![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, May 21, 2015 8:41:14 PM
1) Could they have sold the Diagnostic division?
2) Could ESS (Cutagen) be sold)? Interesting how that deal never closed yet...could have been courting buyers and wanted the best deal. I still dont think this asset is a strategic fit into the company anyway.
3) Could we have a Partnership somewhere aligned to one of our most signficant assets (MANF - RP, Eltoprazine, ESS or maybe even on LymPro)?
Its possible that we wake up tomorrow and the R/S is already converted at a $.05 or $.055 strike price...and we are Up listed on Nasdaq next Tuesday or Wednesday. Its very interesting how the Conference call (next Wed.) was delayed a week after the actual Q1 Earnings announcement.
Stay tuned!!!
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM